{"id":"https://openalex.org/W2948207149","doi":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.540","title":"5PSQ-107 Aspirin and novel oral anticoagulants: reporting of adverse drug reactions","display_name":"5PSQ-107 Aspirin and novel oral anticoagulants: reporting of adverse drug reactions","publication_year":2019,"publication_date":"2019-03-01","ids":{"openalex":"https://openalex.org/W2948207149","doi":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.540","mag":"2948207149"},"language":"en","primary_location":{"id":"doi:10.1136/ejhpharm-2019-eahpconf.540","doi":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.540","is_oa":true,"landing_page_url":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.540","pdf_url":"https://ejhp.bmj.com/content/ejhpharm/26/Suppl_1/A251.1.full.pdf","source":{"id":"https://openalex.org/S3012707348","display_name":"European Journal of Hospital Pharmacy","issn_l":"2047-9956","issn":["2047-9956","2047-9964"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Section 5: Patient Safety and Quality Assurance","raw_type":"proceedings-article"},"volume":null,"type":"conference-paper","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ejhp.bmj.com/content/ejhpharm/26/Suppl_1/A251.1.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110769101","display_name":"Josephine Attard","orcid":"https://orcid.org/0000-0001-6538-893X","observed_orcids":["https://orcid.org/0000-0001-6538-893X"]},"institutions":[{"id":"https://openalex.org/I197854408","display_name":"University of Malta","ror":"https://ror.org/03a62bv60","country_code":"MT","type":"education","lineage":["https://openalex.org/I197854408"]}],"countries":["MT"],"is_corresponding":false,"raw_author_name":"J Attard","raw_affiliation_strings":["University of Malta, Department of Pharmacy, Msida, Malta"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Malta, Department of Pharmacy, Msida, Malta","institution_ids":["https://openalex.org/I197854408"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062330908","display_name":"Janis Vella Szijj","orcid":"https://orcid.org/0000-0001-6061-3608","observed_orcids":["https://orcid.org/0000-0001-6061-3608"]},"institutions":[{"id":"https://openalex.org/I197854408","display_name":"University of Malta","ror":"https://ror.org/03a62bv60","country_code":"MT","type":"education","lineage":["https://openalex.org/I197854408"]}],"countries":["MT"],"is_corresponding":false,"raw_author_name":"J Vella Szijj","raw_affiliation_strings":["University of Malta, Department of Pharmacy, Msida, Malta"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Malta, Department of Pharmacy, Msida, Malta","institution_ids":["https://openalex.org/I197854408"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022086985","display_name":"Anthony Serracino\u2010Inglott","orcid":"https://orcid.org/0000-0003-1196-0376","observed_orcids":["https://orcid.org/0000-0003-1196-0376"]},"institutions":[{"id":"https://openalex.org/I197854408","display_name":"University of Malta","ror":"https://ror.org/03a62bv60","country_code":"MT","type":"education","lineage":["https://openalex.org/I197854408"]}],"countries":["MT"],"is_corresponding":false,"raw_author_name":"A Serracino Inglott","raw_affiliation_strings":["University of Malta, Department of Pharmacy, Msida, Malta"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Malta, Department of Pharmacy, Msida, Malta","institution_ids":["https://openalex.org/I197854408"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I197854408"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.08527132,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A251.1","last_page":"A251"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9595000147819519,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9595000147819519,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10285","display_name":"Venous Thromboembolism Diagnosis and Management","score":0.028300000354647636,"subfield":{"id":"https://openalex.org/subfields/2724","display_name":"Internal Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10065","display_name":"Atrial Fibrillation Management and Outcomes","score":0.006300000008195639,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aspirin","display_name":"aspirin","score":0.9559999704360962},{"id":"https://openalex.org/keywords/direct-oral-anticoagulants","display_name":"direct oral anticoagulants","score":1.0},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.8109999895095825},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"pharmacovigilance","score":0.8820000290870667},{"id":"https://openalex.org/keywords/eudravigilance","display_name":"EudraVigilance","score":0.8450000286102295},{"id":"https://openalex.org/keywords/rivaroxaban","display_name":"rivaroxaban","score":0.9480000138282776},{"id":"https://openalex.org/keywords/apixaban","display_name":"apixaban","score":0.8759999871253967},{"id":"https://openalex.org/keywords/dabigatran","display_name":"dabigatran","score":1.0},{"id":"https://openalex.org/keywords/gastrointestinal-bleeding","display_name":"gastrointestinal bleeding","score":0.9980000257492065},{"id":"https://openalex.org/keywords/patient-reported-side-effects","display_name":"patient-reported adverse events","score":0.8519999980926514},{"id":"https://openalex.org/keywords/thromboprophylaxis","display_name":"thromboprophylaxis","score":0.8730000257492065},{"id":"https://openalex.org/keywords/drug-use-trends","display_name":"drug use trends","score":0.41999998688697815}],"concepts":[{"id":"https://openalex.org/C2778661090","wikidata":"https://www.wikidata.org/wiki/Q420262","display_name":"Rivaroxaban","level":4,"score":0.9121328592300415},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.899437665939331},{"id":"https://openalex.org/C2778810321","wikidata":"https://www.wikidata.org/wiki/Q419345","display_name":"Dabigatran","level":4,"score":0.8168453574180603},{"id":"https://openalex.org/C2777628954","wikidata":"https://www.wikidata.org/wiki/Q18216","display_name":"Aspirin","level":2,"score":0.8049278259277344},{"id":"https://openalex.org/C2780638905","wikidata":"https://www.wikidata.org/wiki/Q414462","display_name":"Apixaban","level":5,"score":0.7903794646263123},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.48458659648895264},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4451373219490051},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4213504493236542},{"id":"https://openalex.org/C2776301958","wikidata":"https://www.wikidata.org/wiki/Q407431","display_name":"Warfarin","level":3,"score":0.26423710584640503},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2562773823738098},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2556063234806061},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.1948399841785431}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/ejhpharm-2019-eahpconf.540","doi":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.540","is_oa":true,"landing_page_url":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.540","pdf_url":"https://ejhp.bmj.com/content/ejhpharm/26/Suppl_1/A251.1.full.pdf","source":{"id":"https://openalex.org/S3012707348","display_name":"European Journal of Hospital Pharmacy","issn_l":"2047-9956","issn":["2047-9956","2047-9964"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Section 5: Patient Safety and Quality Assurance","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.1136/ejhpharm-2019-eahpconf.540","doi":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.540","is_oa":true,"landing_page_url":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.540","pdf_url":"https://ejhp.bmj.com/content/ejhpharm/26/Suppl_1/A251.1.full.pdf","source":{"id":"https://openalex.org/S3012707348","display_name":"European Journal of Hospital Pharmacy","issn_l":"2047-9956","issn":["2047-9956","2047-9964"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Section 5: Patient Safety and Quality Assurance","raw_type":"proceedings-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2948207149.pdf","grobid_xml":"https://content.openalex.org/works/W2948207149.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W6958452152","https://openalex.org/W3174146903","https://openalex.org/W3166882365","https://openalex.org/W2975639692","https://openalex.org/W2807128902","https://openalex.org/W3204291278","https://openalex.org/W2921243516","https://openalex.org/W4415358815","https://openalex.org/W3170173287","https://openalex.org/W3135246563"],"abstract_inverted_index":{"Background":[0],"The":[1,11,129,185],"novel":[2,317],"oral":[3],"anticoagulants":[4],"(NOACs)":[5],"provide":[6],"alternative":[7,24],"options":[8],"for":[9,42,70,88,132,168,182,209,267,316,322],"thromboprophylaxis.":[10],"efficacy":[12,343],"of":[13,36,67,207,250,252,264,304,344,354,361],"antithrombotic":[14],"medications":[15,25,187,318],"such":[16,319,334],"as":[17,61,189,255,320,335],"aspirin":[18,43,71,106,171],"may":[19,326],"vary":[20],"between":[21,82,204],"patients":[22,103,110,214,232],"and":[23,44,47,72,78,84,175,243,272,342],"need":[26],"to":[27,56,95,99,126,149,270,295,313,331,348],"be":[28,293,314,327],"identified.":[29],"Purpose":[30],"To":[31],"carry":[32],"out":[33],"comparative":[34],"analysis":[35],"adverse":[37],"drug":[38],"reactions":[39],"(ADRs)":[40],"reported":[41,81,148,158,166,205,219,230,246,265,290,315],"NOACs.":[45,108],"Material":[46],"methods":[48],"Pharmacovigilance":[49],"(PV)":[50],"reports":[51,123,146,242],"from":[52,121,136],"Eudravigilance":[53],"were":[54,86,111,124,134,147,180,202,228,238],"used":[55,87,286],"compare":[57],"15":[58,142,196],"ADRs":[59,80,100,120,153,179,197,208,227,237,253,266,291,309],"listed":[60],"commonly":[62],"occurring":[63],"in":[64,240,247,289,297,301],"the":[65,73,89,141,156,164,191,210,217,244,284,340,351],"Summaries":[66],"Product":[68],"Characteristics,":[69],"three":[74],"NOACs:":[75],"apixaban,":[76],"dabigatran":[77,173,271],"rivaroxaban.":[79],"2013":[83],"2017":[85],"study.":[90],"A":[91],"questionnaire":[92,218],"was":[93,163],"developed":[94],"collect":[96],"information":[97],"related":[98],"encountered":[101],"by":[102,231,260],"while":[104],"taking":[105,114,117],"or":[107,257,306],"Fifty":[109],"recruited":[112],"(25":[113],"aspirin,":[115],"25":[116],"rivaroxaban).":[118],"Documented":[119],"PV":[122,145,241],"compared":[125,269,330],"patient-reported":[127],"ADRs.":[128,159],"consumption":[130,276,298],"trends":[131,279],"NOACs":[133,345],"analysed":[135],"published":[137],"articles.":[138],"Results":[139],"For":[140,194],"ADRs,":[143],"51,391":[144],"Eudravigilance,":[150],"with":[151],"bleeding-related":[152],"(38,826/51,391)":[154],"being":[155],"commonest":[157,165],"Gastrointestinal":[160],"bleeding":[161],"(n=25,892)":[162],"ADR":[167,223],"rivaroxaban":[169,183,268,282],"(n=12,974),":[170],"(n=5,855),":[172],"(n=5,321)":[174],"apixaban":[176,273],"(n=1,742).":[177],"Reported":[178],"highest":[181,239],"(n=24,832).":[184],"four":[186,211],"differed":[188],"regards":[190],"safety":[192,302,341],"profile.":[193],"all":[195],"investigated,":[198],"statistically":[199],"significant":[200],"differences":[201,296,300],"observed":[203],"cases":[206],"medications.":[212],"Thirty-six":[213],"who":[215],"completed":[216],"at":[220],"least":[221,229],"one":[222],"(aspirin=18,":[224],"rivaroxaban=18).":[225],"Bleeding-related":[226,236],"(aspirin=11,":[233],"rivaroxaban=4).":[234],"Conclusion":[235],"lowest":[245],"questionnaires,":[248],"suggestive":[249],"under-reporting":[251],"considered":[254],"minor":[256],"less":[258],"serious":[259],"patients.":[261],"High":[262],"numbers":[263],"possibly":[274],"reflect":[275],"trends.":[277],"Consumption":[278],"show":[280],"that":[281],"is":[283,346],"most":[285],"NOAC.":[287],"Differences":[288],"could":[292],"due":[294],"trends,":[299],"profiles":[303],"medication":[305],"reporting":[307],"bias.":[308],"are":[310],"more":[311],"likely":[312],"NOACs,":[321],"which":[323],"clinical":[324],"experience":[325],"limited":[328],"when":[329],"conventional":[332],"drugs":[333],"aspirin.":[336],"More":[337],"data":[338],"on":[339],"necessary":[347],"help":[349],"determine":[350],"risk-benefit":[352],"ratio":[353],"therapy.":[355],"References":[356],"and/or":[357],"acknowledgements":[358],"No":[359],"conflict":[360],"interest.":[362]},"counts_by_year":[],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2019-06-14T00:00:00"}